Having previously said it would consider civil or criminal penalties against pharma company Novartis in relation to the manipulation of data for a gene therapy medication, a U.S. Food and Drug Administration (FDA) spokesperson has said the agency will not now punish the company.
The U.S. FDA has a long history of protecting the interests of the pharmaceutical industry. It has long been seeking the goal that vitamins, minerals, and other essential micronutrients are limited to low multiples of the so-called Recommended Dietary Allowance (RDA) when contained in supplements, for example. Under such a scenario, higher dose supplements would essentially be treated as prescription drugs. But while seeking this draconian goal the FDA has done almost nothing to protect the American public from the dangers of toxic pharmaceutical drugs.
In clinical practice, so dangerous has the pharmaceutical approach to medicine become that orthodox doctors, hospitals and their treatments have been shown in the Journal of the American Medical Association (JAMA) to be the third leading cause of death in the United States, exceeded only by deaths from heart disease and cancer. The study, published in July 2000, also found that between 4 percent and 18 percent of patients experience adverse effects in outpatient settings, with 116 million extra physician visits; 77 million extra prescriptions; 17 million emergency department visits; 8 million hospitalizations; 3 million long-term admissions; 199,000 additional deaths; and $77 billion in extra costs.
Similarly, in yet another vivid demonstration of the dangers of pharmaceutical medicine, a JAMA study published in 1998 estimated that in 1994 around 2,216,000 hospitalized patients in the United States had suffered a serious adverse drug reaction (ADR) and that 106,000 suffered a fatal ADR.
The fact that the FDA continues to allow the sale of toxic pharmaceutical drugs tells us everything we need to know about where its primary allegiance lies.